# FMC-220

Source: https://onco.cc/drugs/fmc-220/  
OnCo record `fmc-220` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

FMC-220 is an experimental covalent small molecule from Frontier Medicines, at a stage the company does not state for tumours with the TP53 Y220C mutation.

## Summary

FMC-220 is a covalent small molecule from Frontier Medicines. A covalent activator of the p53 Y220C mutant protein, designed to restore p53 tumour-suppressor function selectively. The company does not state its stage; it is aimed at tumours with the TP53 Y220C mutation. No clinical trial naming it is registered on ClinicalTrials.gov. No registered trial on ClinicalTrials.gov; the page gives no stage. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Last checked: 2026-11-03
- Tags: pipeline
- Code: FMC-220
- Modality: Covalent small molecule
- Mechanism: A covalent activator of the p53 Y220C mutant protein, designed to restore p53 tumour-suppressor function selectively.

## Sources

- Frontier Medicines: frontiermeds.com: https://www.frontiermeds.com/precision-pipeline/fmc-220-p53-y220c-activator

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [TP53](https://onco.cc/targets/tp53/)
- companies: [Frontier Medicines](https://onco.cc/companies/frontier-medicines/)

---
JSON: https://onco.cc/api/v1/entities/fmc-220.json